Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.

Intelence

Last reviewed on RxList: 11/27/2018
Intelence Side Effects Center

Last reviewed on RxList 11/27/2018

Intelence (etravirine) is an antiviral medication used with other medications to treat HIV, which causes the acquired immunodeficiency syndrome (AIDS). This drug is not a cure for HIV or AIDS, and it is usually given after other antiviral drugs have been tried unsuccessfully. Common side effects of Intelence include nausea, rash, numbness or tingly feeling in your hands or feet, dizziness, drowsiness, blurred vision, upset stomach, constipation, heartburn, dry mouth, unusual dreams, or changes in the shape or location of body fat (especially in your arms, legs, face, neck, breasts, and waist).

The recommended adult oral dose of Intelence is 200 mg (one 200 mg tablet or two 100 mg tablets) taken twice daily following a meal. Pediatric dose is based on body weight. Intelence may interact with blood thinners, clopidogrel, darunavir, lopinavir/ritonavir, dexamethasone, diazepam, cyclosporine, cholesterol medications, maraviroc, methadone, sildenafil, sirolimus, tacrolimus, antibiotics, antifungals, or heart rhythm medications. Many other medicines can interact with Intelence, or make it less effective. Tell your doctor all medications and supplements you use. During pregnancy, Intelence should be used only when prescribed. It is unknown if this medication passes into breast milk. Because breast milk can transmit HIV, do not breastfeed.

Our Intelence (etravirine) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

A Timeline of the HIV/AIDS Pandemic See Slideshow
Intelence Consumer Information

Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).

Seek medical treatment if you have a serious drug reaction that can affect many parts of your body. Symptoms may include: skin rash, fever, swollen glands, muscle aches, severe weakness, unusual bruising, or yellowing of your skin or eyes.

Call your doctor at once if you have:

  • unexplained muscle pain, tenderness, or weakness;
  • fever, unusual tiredness;
  • dark colored urine; or
  • any type of skin rash, no matter how mild.

Etravirine affects your immune system, which may cause certain side effects (even weeks or months after you've taken this medicine). Tell your doctor if you have:

  • signs of a new infection--fever, night sweats, swollen glands, cold sores, cough, wheezing, diarrhea, weight loss;
  • trouble speaking or swallowing, problems with balance or eye movement, weakness or prickly feeling; or
  • swelling in your neck or throat (enlarged thyroid), menstrual changes, impotence.

Common side effects may include:

  • diarrhea;
  • numbness or tingly feeling in your hands or feet;
  • rash; or
  • changes in the shape or location of body fat (especially in your arms, legs, face, neck, breasts, and waist).

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Intelence (Entravirine Tablets)

QUESTION

What is HIV? See Answer
Intelence Professional Information

SIDE EFFECTS

The following adverse reactions are described in greater detail in other sections:

  • Severe skin and hypersensitivity reactions [see WARNINGS AND PRECAUTIONS].

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Clinical Trials Experience In Adults

The safety assessment is based on all data from 1203 subjects in the Phase 3 placebo-controlled trials, TMC125-C206 and TMC125-C216, conducted in antiretroviral treatment-experienced HIV-1-infected adult subjects, 599 of whom received INTELENCE (200 mg twice daily). In these pooled trials, the median exposure for subjects in the INTELENCE arm and placebo arm was 52.3 and 51.0 weeks, respectively. Discontinuations due to adverse drug reactions (ADRs) were 5.2% in the INTELENCE arm and 2.6% in the placebo arm.

The most frequently reported ADR at least Grade 2 in severity was rash (10.0%). Stevens-Johnson syndrome, drug hypersensitivity reaction and erythema multiforme were reported in less than 0.1% of subjects during clinical development with INTELENCE [see WARNINGS AND PRECAUTIONS]. A total of 2.2% of HIV-1-infected subjects in Phase 3 trials receiving INTELENCE discontinued due to rash. In general, in clinical trials, rash was mild to moderate, occurred primarily in the second week of therapy, and was infrequent after Week 4. Rash generally resolved within 1 to 2 weeks on continued therapy. The incidence of rash was higher in women compared to men in the INTELENCE arm in the Phase 3 trials (rash ≥ Grade 2 was reported in 9/60 [15.0%] women versus 51/539 [9.5%] men; discontinuations due to rash were reported in 3/60 [5.0%] women versus 10/539 [1.9%] men) [see WARNINGS AND PRECAUTIONS]. Patients with a history of NNRTI-related rash did not appear to be at increased risk for the development of INTELENCE-related rash compared to patients without a history of NNRTI-related rash.

Common Adverse Reactions

Clinical ADRs of moderate intensity or greater (greater than or equal to Grade 2) and reported in at least 2% of subjects treated with INTELENCE and occurring at a higher rate compared to placebo (excess of 1%) are presented in Table 2. Laboratory abnormalities considered ADRs are included in Table 3.

Table 2: Adverse Drug Reactions (Grades 2 to 4) in at Least 2% of Adult Subjects (Pooled TMC125- C206 and TMC125-C216 Trials)

Preferred Term INTELENCE + BR
N=599
%
Placebo + BR
N=604
%
Rash 10% 3%
Peripheral neuropathy 4% 2%
N=total number of subjects per treatment group; BR=background regimen

Less Common Adverse Reactions

Treatment-emergent ADRs occurring in less than 2% of subjects (599 subjects) receiving INTELENCE and of at least moderate intensity (greater than or equal to Grade 2) are listed below by body system:

Cardiac Disorders: myocardial infarction, angina pectoris, atrial fibrillation

Ear and Labyrinth Disorders: vertigo

Eye Disorders: blurred vision

Gastrointestinal Disorders: gastroesophageal reflux disease, flatulence, gastritis, abdominal distension, pancreatitis, constipation, dry mouth, hematemesis, retching, stomatitis

General Disorders and Administration Site Conditions: sluggishness

Hematologic Disorders: hemolytic anemia

Hepatobiliary Disorders: hepatic failure, hepatomegaly, cytolytic hepatitis, hepatic steatosis, hepatitis

Immune System Disorders: drug hypersensitivity, immune reconstitution syndrome

Metabolism and Nutrition Disorders: diabetes mellitus, anorexia, dyslipidemia

Nervous System Disorders: paresthesia, somnolence, convulsion, hypoesthesia, amnesia, syncope, disturbance in attention, hypersomnia, tremor

Psychiatric Disorders: anxiety, sleep disorders, abnormal dreams, confusional state, disorientation, nervousness, nightmares

Renal and Urinary Disorders: acute renal failure

Reproductive System and Breast Disorders: gynecomastia

Respiratory, Thoracic and Mediastinal Disorders: exertional dyspnea, bronchospasm

Skin and Subcutaneous Tissue Disorders: night sweats, lipohypertrophy, prurigo, hyperhidrosis, dry skin, swelling face

Additional ADRs of at least moderate intensity observed in other trials were acquired lipodystrophy, angioneurotic edema, erythema multiforme and hemorrhagic stroke, each reported in no more than 0.5% of subjects.

Laboratory Abnormalities in Treatment-Experienced Patients

Selected Grade 2 to Grade 4 laboratory abnormalities that represent a worsening from baseline observed in adult subjects treated with INTELENCE are presented in Table 3.

Table 3: Selected Grade 2 to 4 Laboratory Abnormalities Observed in Treatment-Experienced Subjects (Pooled TMC125-C206 and TMC125-C216 Trials)

Laboratory Parameter DAIDS Toxicity Range INTELENCE + BR
N=599
%
Placebo + BR
N=604
%
GENERAL BIOCHEMISTRY
  Pancreatic amylase      
    Grade 2 > 1.5–2 x ULN 7% 8%
    Grade 3 > 2–5 x ULN 7% 8%
    Grade 4 > 5 x ULN 2% 1%
  Lipase      
    Grade 2 > 1.5–3 x ULN 4% 6%
    Grade 3 > 3–5 x ULN 2% 2%
    Grade 4 > 5 x ULN 1% < 1%
  Creatinine      
    Grade 2 > 1.4–1.8 x ULN 6% 5%
    Grade 3 > 1.9–3.4 x ULN 2% 1%
    Grade 4 > 3.4 x ULN 0% < 1%
HEMATOLOGY      
  Decreased hemoglobin      
    Grade 2 90–99 g/L 2% 4%
    Grade 3 70–89 g/L < 1% < 1%
    Grade 4 < 70 g/L < 1% < 1%
  White blood cell count      
    Grade 2 1,500–1,999/mm3 2% 3%
    Grade 3 1,000–1,499/mm3 1% 4%
    Grade 4 < 1,000/mm3 1% < 1%
  Neutrophils      
    Grade 2 750–999/mm3 5% 6%
    Grade 3 500–749/mm3 4% 4%
    Grade 4 < 500/mm3 2% 3%
  Platelet count      
    Grade 2 50,000–99,999/mm3 3% 5%
    Grade 3 25,000–49,999/mm3 1% 1%
    Grade 4 < 25,000/mm3 < 1% < 1%
LIPIDS AND GLUCOSE
  Total cholesterol      
    Grade 2 > 6.20–7.77 mmol/L
240–300 mg/dL
20% 17%
    Grade 3 > 7.77 mmol/L
> 300mg/dL
8% 5%
  Low density lipoprotein      
    Grade 2 4.13–4.9 mmol/L
160–190 mg/dL
13% 12%
    Grade 3 > 4.9 mmol/L
> 190mg/dL
7% 7%
  Triglycerides      
    Grade 2 5.65–8.48 mmol/L
500–750 mg/dL
9% 7%
    Grade 3 8.49–13.56 mmol/L
751–1200 mg/dL
6% 4%
    Grade 4 > 13.56 mmol/L
> 1200 mg/dL
4% 2%
  Elevated glucose levels      
    Grade 2 6.95–13.88 mmol/L
161–250 mg/dL
15% 13%
    Grade 3 13.89–27.75 mmol/L
251–500 mg/dL
4% 2%
    Grade 4 > 27.75 mmol/L
> 500mg/dL
0% < 1%
HEPATIC PARAMETERS
  Alanine amino transferase      
    Grade 2 2.6–5 x ULN 6% 5%
    Grade 3 5.1–10 x ULN 3% 2%
    Grade 4 > 10 x ULN 1% < 1%
  Aspartate amino transferase      
    Grade 2 2.6–5 x ULN 6% 8%
    Grade 3 5.1–10 x ULN 3% 2%
    Grade 4 > 10 x ULN < 1% < 1%
ULN=Upper Limit of Normal; BR=background regimen

Patients Co-Infected With Hepatitis B and/or Hepatitis C Virus

In Phase 3 trials TMC125-C206 and TMC125-C216, 139 subjects (12.3%) with chronic hepatitis B and/or hepatitis C virus co-infection out of 1129 subjects were permitted to enroll. AST and ALT abnormalities occurred more frequently in hepatitis B and/or hepatitis C virus co-infected subjects for both treatment groups. Grade 2 or higher laboratory abnormalities that represent a worsening from baseline of AST, ALT or total bilirubin occurred in 27.8%, 25.0% and 7.1% respectively, of INTELENCE-treated co-infected subjects as compared to 6.7%, 7.5% and 1.8% of non-co-infected INTELENCE-treated subjects. In general, adverse events reported by INTELENCE-treated subjects with hepatitis B and/or hepatitis C virus co-infection were similar to INTELENCE-treated subjects without hepatitis B and/or hepatitis C virus co-infection.

Clinical Trials Experience In Pediatric Subjects (2 Years To Less Than 18 Years Of Age)

The safety assessment in pediatric subjects is based on two single-arm trials. TMC125-C213 is a Phase 2 trial in which 101 antiretroviral treatment-experienced HIV-1 infected pediatric subjects 6 years to less than 18 years of age received INTELENCE in combination with other antiretroviral agents (Week 24 analysis). TMC125-C234/IMPAACT P1090 is a Phase 1/2 trial in which 20 antiretroviral treatment-experienced HIV-1 infected pediatric subjects 2 years to less than 6 years of age received INTELENCE in combination with other antiretroviral agents (Week 24 analysis) [see Clinical Studies].

In TMC125-C213, the frequency, type and severity of adverse drug reactions in pediatric subjects 6 years to less than 18 years of age were comparable to those observed in adult subjects, except for rash which was observed more frequently in pediatric subjects. The most common adverse drug reactions in at least 2% of pediatric subjects were rash and diarrhea. Rash was reported more frequently in female subjects than in male subjects (rash ≥ Grade 2 was reported in 13/64 [20.3%] females versus 2/37 [5.4%] males; discontinuations due to rash were reported in 4/64 [6.3%] females versus 0/37 [0%] males). Rash (greater than or equal to Grade 2) occurred in 15% of pediatric subjects from 6 years to less than 18 years of age. In the majority of cases, rash was mild to moderate, of macular/papular type, and occurred in the second week of therapy. Rash was self-limiting and generally resolved within 1 week on continued therapy. The safety profile for subjects who completed 48 weeks of treatment was similar to the safety profile for subjects who completed 24 weeks of treatment.

In TMC125-C234/IMPAACT P1090, the frequency, type and severity of adverse drug reactions in pediatric subjects 2 years to less than 6 years of age through Week 24 were comparable to those observed in adults. The most common adverse drug reactions (any grade) of pediatric subjects were rash (50% [10/20]) and diarrhea (25% [5/20]). In this age group, no subjects had Grade 3 or Grade 4 rash and no subjects discontinued prematurely due to rash. One subject discontinued etravirine due to asymptomatic lipase elevation.

Postmarketing Experience

The following events have been identified during postmarketing use of INTELENCE. Because these events are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune System Disorders: Severe hypersensitivity reactions including DRESS and cases of hepatic failure have been reported [see WARNINGS AND PRECAUTIONS].

Musculoskeletal and Connective Tissue Disorders: rhabdomyolysis

Skin and Subcutaneous Tissue Disorders: Fatal cases of toxic epidermal necrolysis have been reported [see WARNINGS AND PRECAUTIONS].

Read the entire FDA prescribing information for Intelence (Entravirine Tablets)

Related Resources for Intelence

Read the Intelence User Reviews »

© Intelence Patient Information is supplied by Cerner Multum, Inc. and Intelence Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

SLIDESHOW

A Timeline of the HIV/AIDS Pandemic See Slideshow

Health Solutions From Our Sponsors

CONTINUE SCROLLING FOR RELATED SLIDESHOW